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Antibody (Ab)-dependent enhancement can exacer-
bate dengue virus (DENV) infection due to cross-reac-
tive Abs from an initial DENV infection, facilitating
replication of a second DENV. Zika virus (ZIKV)
emerged in DENV-endemic areas, raising questions
about whether existing immunity could affect these
related flaviviruses. We show that mice born with
circulating maternal Abs against ZIKV develop severe
disease upon DENV infection. Compared with pups of
naive mothers, those born to ZIKV-immune mice
lacking type I interferon receptor in myeloid cells
(LysMCre+Ifnar1fl/fl) exhibit heightened disease and
viremia upon DENV infection. Passive transfer of IgG
isolated from mice born to ZIKV-immune mothers re-
sulted in increased viremia in naive recipient mice.
Treatment with Abs blocking inflammatory cytokine
tumor necrosis factor linked to DENV disease or Abs
blocking DENV entry improved survival of DENV-in-
fected mice born to ZIKV-immune mothers. Thus, the
maternal Ab response to ZIKV infection or vaccination
might predispose to severe dengue disease in infants.
INTRODUCTION
Since the emergence of Zika virus (ZIKV) in dengue virus (DENV)
endemic areas, a question that remains unanswered is how ZIKV
and DENV immunity reciprocally affect each other in the context
of sequential infections. DENV is the leading mosquito-trans-
mitted viral infection globally (Guzman et al., 2010), with an esti-
mated 390 million infections per year, and results in clinical
symptoms ranging from unapparent to life threatening (Bhatt
et al., 2013). DENV disease creates a substantial burden on pub-
lic health resources, with more than 3 billion people at risk for
infection worldwide (Shepard et al., 2016). DENV is a flavivirus
and circulates as four different serotypes (DENV1–4) that vary
by 25%–40% at the amino acid level. Although primary DENVinfection usually manifests as a self-limiting febrile illness, sec-
ondary infections with a heterotypic serotype can result in
dengue hemorrhagic fever/dengue shock syndrome (DHF/
DSS), also referred to as severe dengue, which is associated
with vascular leakage, hemodynamic shock, and death. One
model for the pathogenesis of severe dengue involves the phe-
nomenon of antibody (Ab)-dependent enhancement (ADE),
where circulating cross-reactive Abs from the first DENV infec-
tion bind to the second DENV and facilitate its entry and replica-
tion in Fcg receptor-expressing cells (Halstead, 2007).
ZIKV, the causal agent of congenital Zika syndrome (World
Health Organization, 2016), is genetically and antigenically
similar to DENV, with 56% amino acid identity (Chang et al.,
2017), and cross-reactivity between the two viruses at the Ab
epitope level has been documented extensively (Bardina et al.,
2017; Charles and Christofferson, 2016; Dejnirattisai et al.,
2016; Kawiecki and Christofferson, 2016; Priyamvada et al.,
2016; Stettler et al., 2016; Swanstrom et al., 2016). Indeed,
studies have begun to evaluate the impact of the cross-reactive
Ab response in protection against or pathogenesis of ZIKV and
DENV infections. Although some cross-reactive monoclonal
Abs generated against DENV protect against ZIKV (Barba-
Spaeth et al., 2016; Fernandez et al., 2017), others generated
against ZIKV can enhance DENV infection (Stettler et al.,
2016). In the context of polyclonal Ab responses, prior ZIKV
infection resulted in increased peak DENV viremia in macaques
(George et al., 2017) and DENV-immune plasma enhanced ZIKV
infection and disease severity in Stat2/ mice (Bardina et al.,
2017). These studies suggest that ADE can occur in different
ZIKV and DENV infection scenarios.
In humans,maternal Abs fromDENV-immunemothers can pro-
vide protection, enhancement, or no effect when passively trans-
ferred to an infant (Chau et al., 2009; Elong Ngono and Shresta,
2018; Halstead et al., 2002; Simmons et al., 2007). As levels of
maternal Abs in infants fall to subneutralizing levels, there is an
increased risk of developing severe dengue (Halstead et al.,
2002). As the geographic range of ZIKV expands, it will become
possible for mothers to be exposed to ZIKV and their infants to
be infected with DENV. It currently remains unknown whether
ZIKV Abs can result in enhancement or protection when trans-
ferred passively to infants. Here, we develop a model of severe
dengue in mice born to ZIKV-immune mothers using established 
LysMCre+Ifnar1fl/fl mouse models of ZIKV and DENV infection 
(Elong Ngono et al., 2017; Pinto et al., 2015; Tang et al., 2016). 
Our results demonstrate that maternally acquired ZIKV Abs can 
enhance DENV infection and disease severity in young mice.
RESULTS
Decreased Survival of Pups Born to ZIKV-Immune 
Mothers after DENV2 Infection
To investigate whether maternal Abs from ZIKV-immune 
mothers conferred protection or promoted severe dengue 
disease in young mice, we inoculated 4- to 5-week-old 
LysMCre+Ifnar1fl/fl pups born to ZIKV-immune or naive mothers 
with DENV2-S221 and monitored them for weight loss, clinical 
signs, and survival. Pups born to ZIKV-immune mothers had 
similar immune cell numbers and frequency in the spleen as 
those born to naive mothers (Figure S1). Animals born to long-
term (8–12 months) ZIKV-immune mothers and challenged with 
DENV2 had increased clinical scores compared with naive 
LysMCre+Ifnar1fl/fl mice, although both groups exhibited similar 
weight loss (Figures 1A–1C). Most of the mice in the naive control 
group recovered from DENV infection, whereas 100% mice born 
to long-term (8–12 months) ZIKV-immune mothers died by day 6 
post infection (p.i.) (Figures 1A, 1B, and 1D). To determine 
whether short-term ZIKV infection period in mothers also 
affected the outcome of DENV infection in their pups, we as-
sessed clinical score, weight loss, and survival in pups born to 
short-term (2 months) ZIKV-immune mothers (Figures 1E–1H). 
Both naive and ZIKV-immune groups exhibited similar weight 
loss after DENV2 challenge (Figure 1G), yet mice born to ZIKV-
immune mothers had increased clinical scores and decreased 
survival compared with those born to naive mothers (Figures 
1E, 1F, and 1H). These results demonstrate that, at 4–5 weeks 
of age, pups born to ZIKV-immune but not naive mice develop 
lethal disease upon challenge with DENV2.
Increased DENV2 Burden in Pups Born to ZIKV-
Immune Mice
To determine whether enhanced disease severity in pups born to 
long-term (6–13 months) ZIKV-immune mothers was associated 
with increased levels of DENV2 infection, we compared viral 
RNA levels in pups born to ZIKV-immune versus naive mothers 
at day 3 p.i. DENV2 RNA levels were increased significantly in 
the serum (5-fold, ***p < 0.001), spleen (13-fold, **p < 0.01), 
and liver (8-fold, **p < 0.01) in pups born to ZIKV-immune 
mothers relative to naive pups (Figure 1I). Thus, severe dengue 
disease manifestations correlated with increased DENV2 tissue 
burden in mice born to ZIKV-immune mothers.
To examine whether enhanced disease severity in mice born 
to short-term ZIKV-infected mothers was due to increased 
DENV infection, we measured levels of infectious DENV in 
pups born to short-term (2 months) ZIKV-immune or naive 
mothers at day 3 p.i. Infectious DENV levels were higher in the 
serum (25-fold, ***p < 0.001), spleen (3-fold, **p < 0.01), and liver 
(9-fold, **p < 0.01) in pups born to ZIKV-immune than to naive 
mothers (Figure 1J), confirming the correlation between severe 
dengue disease and increased DENV2 burden in mice born to 
ZIKV-immune mothers.Improved Clinical Phenotypes and Decreased ZIKV
Burden in Pups Born to ZIKV-Immune Compared with
Naive or DENV-Immune Mothers
As we observed a negative impact of maternal ZIKV immunity in
pups upon challenge with DENV, we next examined the recip-
rocal conditions by testing whether maternal ZIKV or DENV im-
munity influenced the outcome of subsequent challenge of
pups with ZIKV. When pups born to ZIKV-immune mothers
were challenged with ZIKV, they had significantly less infectious
ZIKV in the serum, spleen, liver, brain, and eyes compared with
pups born to naive or DENV2-immune mothers (Figure S2A).
Similar levels of infectious ZIKV were detected in pups born to
DENV2-immune and naive mothers, with the exception of the
liver where maternal DENV immunity had a protective effect (Fig-
ure S2A). Consistent with these data, pups born to ZIKV-immune
mothers and challenged with ZIKV had better clinical scores and
less weight loss than those born to naive mice (Figures S2B,
S2C, and S2F). In contrast, pups born to DENV2-immune
mothers and challenged with ZIKV had clinical scores similar
to those born to naive mice but had a slightly different weight
change (Figures S2D, S2E, and S2G). These data suggest that
ZIKV maternal immunity protects against ZIKV challenge in in-
fancy whereas DENV maternal immunity has a more neutral ef-
fect. As expected (Ng et al., 2014), pups born to DENV2-immune
mothers and then challenged with DENV2 exhibited better clin-
ical scores and no weight loss compared with pups born to naive
mothers (Figures S3A and S3B), indicating that maternal DENV
immunity protects against homologous DENV challenge. Thus,
at least under the conditions tested, the enhanced pathogenesis
observed in pups from ZIKV-immune mothers that are chal-
lenged with DENV2 is unique and does not occur when pups
born to ZIKV-immune or DENV2-immune mothers are chal-
lenged with ZIKV.
Maternally Acquired ZIKV Abs Bind but Do Not
Neutralize DENV2
To begin defining the mechanism of maternal ZIKV Ab-mediated
DENV pathogenesis, we tested maternal ZIKV Abs from the
serum of 4- to 5-week-old pups from ZIKV-immune mothers
for their capacity to bind and neutralize DENV2. Sera of pups
born to ZIKV-immune but not naive mothers contained ZIKV-
and DENV2-reactive Abs (Figures 2A and 2B). However, these
sera neutralized ZIKV but not DENV2 infection in U937-DC-
SIGN cells and even appeared to enhance DENV2 infection (Fig-
ures 2C and 2D). Levels of ZIKV-binding Abs in pups born to
short-term (2 months) mothers was lower than the levels
observed in pups born to long-term ZIKV-immune mothers,
whereas DENV2-binding Ab levels were similar between the
two groups of mice (Figures 2E and 2F). Thus, maternal Abs in
4- to 5-week-old pups born to ZIKV-immune mothers cross-
react with but do not cross-neutralize DENV2 in vitro.
To understand the lack of enhancement of ZIKV pathogenesis
in pups with maternally acquired DENV2 Abs, we analyzed the
binding and neutralization capacity of sera from 4- to 5-week
old pups born to DENV2-immune mothers. Serum samples
from mice born to DENV2-immune mothers bound to DENV2,
but not ZIKV (Figures S3C and S3D). Additionally, these sera
could neutralize DENV2 (Figure S3E). Thus, the absence of
enhanced ZIKV pathogenesis in pups born to DENV2-immune
Figure 1. Mice Born to ZIKV-ImmuneMothers
Have Increased Dengue Disease Severity and
DENV Burden
Four- to 5-week-old LysMCre+Ifnar1fl/fl mice born to
mothers previously infected with ZIKV strain SD001
(106 focus-forming units [FFU] via retro-orbital route)
or to naive mothers were challenged with DENV2
strain S221 (106 FFU via tail vein).
(A) Clinical scores of infectedmice (n = 11) from naive
mothers (n = 2).
(B) Clinical scores of infected mice (n = 15) from
ZIKV-immune mothers infected for 8–12 months
(n = 3).
(C and D) Weight loss and survival data of infected
mice from naive (open squares) versus ZIKV-immune
mothers infected for 8–12 months (black circles).
(E) Clinical scores of infected mice (n = 8) from naive
mothers (n = 2).
(F) Clinical scores of infected mice (n = 8) from ZIKV-
immune mothers infected for 2 months (n = 2).
(G and H) Weight loss and survival data of infected
mice from naive (open squares) versus ZIKV-immune
mothers infected for 2 months (gray circles). To
determine DENV viral burden, we euthanized mice at
3 days p.i. and harvested serum, spleens, and livers.
(I) The levels of DENV RNA from each tissue were
measured via qRT-PCR. Viral RNA levels in the
serum, spleen, and liver of DENV2-infected
pups (open squares, n = 11) from naive mothers
(n = 2) were compared with pups (black circles,
n = 13) from ZIKV-immune mothers infected for
6–13 months (n = 4).
(J) The levels of infectious DENV2weremeasured via
focus-forming assay in the serum, spleen, and liver
of DENV2-infected pups (open squares, n = 7) from
naive mothers (n = 2) and pups (gray circles, n = 7)
from ZIKV-immune mothers infected for 2 months
(n = 2).
Data in (C) and (G) were pooled from two indepen-
dent experiments and are expressed as mean ±
SEM; unpaired Student’s t test of groups for each
day. In (D) and (H) the log-rank test (***p % 0.001,
**p < 0.01) was used. Data in (I) and (J) were pooled
from two independent experiments. Mann-Whitney
test (***p < 0.001, **p < 0.01).
Figure 2. Sera from Mice Born to ZIKV-Im-
mune Mothers Neutralize ZIKV but Not
DENV2 Infection
Serum was collected from 4- to 5-week-old
LysMCre+Ifnar1fl/fl mice born to mothers previously
infected with ZIKV strain SD001 (106 FFU via retro-
orbital route) or naive mothers. Serum of pups (open
squares, n = 10) from naive mothers (n = 2) were
compared with pups (black circles, n = 13) from
ZIKV-immune mothers infected for 6–13 months
(n = 4).
(A–D) Anti-ZIKV IgG (A) and anti-DENV IgG (B) were
detected via ELISA. Neutralization capacity was
assessed against (C) ZIKV SD001 and (D) DENV2
S221 via U937-DC-SIGN cells and a flow cytometry-
based assay (Wen et al., 2017). Dotted line indicates
limit of detection for ELISA and 50% or 0% neutral-
ization line for the neutralization assay. Serum of
pups (black circles, n = 13) from ZIKV-immune
mothers infected for 6–13 months (n = 4) were
compared with serum of pups (open squares, n = 10)
from ZIKV-immune mothers infected for 2 months
(n = 3).
(E and F) Anti-ZIKV IgG (E) and anti-DENV2 IgG (F)
were detected via ELISA.
Data are pooled from three independent experi-
ments and are expressed as mean ± SEM.mothers is likely due to a lack of ZIKV binding by maternally ac-
quired DENV2 Abs.
Increased Viral Burden in DENV2-Infected Mice with 
Passively Transferred IgG from Pups Born to ZIKV-
Immune Mothers
To confirm that maternal ZIKV Abs were responsible for enhanced 
DENV2 infection, we isolated serum immunoglobulin G (IgG) from 
4- to 5-week-old pups born to ZIKV-immune or naive mothers and 
then passively transferred it into age-matched naive 4- to 5-week 
old LysMCre+Ifnar1fl/fl recipient mice immediately prior to infec-
tion. Two different preparations of IgG that were isolated from 
pooled sera collected from pups born to ZIKV-immune or naive 
mothers showed binding to both ZIKV and DENV but no neutral-
izing activity against DENV (Figures S4A–S4D). Mice that received 
145 mg (amount that was determined from IgG isolated from a sin-
gle mouse) of IgG from pups born to ZIKV-immune mothers had 
higher DENV2 RNA levels in the serum (7-fold, **p < 0.01) and 
spleen (4-fold, *p < 0.05) than mice receiving IgG from pups 
born to naive mothers at day 3 after challenge (Figure 3A). These 
results imply that maternally acquired IgG obtained from ZIKV-im-
mune mothers contributes to the enhanced DENV2 infection and 
pathogenesis phenotypes observed after DENV2 challenge of 
pups at 4–5 weeks of age. As expected, when 10-fold less IgG 
was transferred to naive 4- to 5-week old recipient mice, no differ-
ence in DENV2 RNA levels in tissues was observed between mice 
that received IgG from ZIKV-immune versus naive mothers (Fig-
ure 3B), revealing the Ab concentration-dependent nature of the 
DENV2 enhancement phenotype.TNF Levels Are Increased in Mice with Passively
Transferred ZIKV IgG upon DENV2 Challenge
We next determined whether tumor necrosis factor (TNF) levels
were increased in mice that received IgG from pups born to
ZIKV-immune pups relative to mice that received IgG from naive
pups. Human studies have shown that patients with severe
dengue have higher levels of several pro-inflammatory cyto-
kines, including TNF, compared with individuals with mild
dengue (Green et al., 1999; Hober et al., 1993; Kittigul et al.,
2000; Wang et al., 2007), and in a small observational study indi-
viduals on anti-TNF Ab therapy did not develop DHF/DSS (De-
ligny et al., 2014). Consistent with several studies demonstrating
that the lethal ADE-mediated dengue disease in mice is TNF
dependent (Ng et al., 2014; Phanthanawiboon et al., 2016;
Shresta et al., 2006; Watanabe et al., 2015; Zellweger et al.,
2010), TNF levels were increased in ZIKV IgG recipient mice
compared with naive IgG recipient mice (Figure S4E), implying
that ZIKV IgG treatment potentiates TNF induction.
TNF Blockade Decreases DENV2-Induced Lethality in
Mice Born to ZIKV-Immune Mothers
To assess the significance of TNF induction in our mouse model,
we determined whether DENV2-induced lethal disease in pups
born to ZIKV-immune mice was mediated by TNF by performing
blocking experiments with a neutralizing anti-TNF Ab. Mice born
to ZIKV-immune mothers were inoculated with DENV2 and
administered 100 mg of an anti-TNF or an isotype control Ab on
days 1, 2, and 3 p.i. The anti-TNF Ab-treated group exhibited
improved clinical scores, weight gain, and increased survival
Figure 3. Passive Transfer of IgG Isolated
from Mice Born to ZIKV-Immune Mothers
into Naive Mice Increases Viral Burden upon
DENV2 Challenge
(A and B) IgG was isolated from serum of 36
pups born to ZIKV-immune mothers infected for
6–12 months (n = 8) or from 32 age-matched naive
mice from naive LysMCre+Ifnar1fl/fl mothers (n = 7).
145 mg (A) or 14.5 mg (B) of purified IgG isolated from
pups born to ZIKV-immune mothers (ZIKV IgG) or
naive mothers (naive IgG) was passively transferred
into naive 4- to 5-week-old LysMCre+Ifnar1fl/fl
recipient mice, followed by challenge of the
passively transferred recipient mice with 2 3 105
FFU of DENV2 strain S221 via tail vein injection.
Tissues were harvested 3 days p.i. and DENV2 RNA
levels in the serum, spleen, and liver were quantified
by qRT-PCR. n = 6–7 ZIKV IgG recipient mice and
n = 6 naive IgG recipient mice. Mann-Whitney test
(**p < 0.01, *p < 0.05).compared with isotype control Ab-treated mice (Figures 4A–4D).
This result is consistent with the hypothesis that DENV2-infected
pups born to ZIKV-immune mothers have increased disease
severity through ADE and overexuberant production of pro-in-
flammatory cytokines.
Monoclonal Ab Treatment Decreases DENV2-Induced
Lethality in Mice Born to ZIKV-Immune Mothers
The original studies demonstrating ADE-mediated lethal dengue
disease in mice showed that neutralizing DENV monoclonal Abs
(mAbs) that blocked fusion could abrogate ADE (Balsitis et al.,
2010; Zellweger et al., 2010). Given these data, we assessed
whether the DENV2-induced lethal disease in pups born to
ZIKV-immune mothers could also be prevented via treatment
with neutralizing mAbs. We tested two human EDE1 mAbs (C8
and C10) that cross-neutralize different DENV serotypes and
ZIKV (Dejnirattisai et al., 2015; Fernandez et al., 2017; Swan-
strom et al., 2016) for their ability to reduce disease severity in
DENV2-infected pups born to ZIKV-immune LysMCre+Ifnar1fl/fl
mothers. Administration of 100 mg of EDE1 C8 or EDE1 C10 Ab
on days 1, 2, and 3 p.i. decreased dengue disease compared
with treatment with PBS alone, based on clinical scores (Figures
4E–4G), weight loss (Figure 4H), and survival (Figure 4I). Thus,
administration of EDE1 mAbs can prevent severe dengue dis-
ease in mice born to ZIKV-immune mothers.
DISCUSSION
Currently, little is known about how prior ZIKV immunity affects
DENV pathogenesis and infection in vivo. One study showed
that previous ZIKV exposure increased peak DENV viremia in
macaques (George et al., 2017), and another reported
enhanced DENV pathogenesis in mice administered a ZIKVmAb (Stettler et al., 2016). Consistent
with these findings, our data show
increased viral burden, worsened clinical
signs, and decreased survival in mice
born to ZIKV-immune mothers relative tothose born to naive mothers. Our study demonstrates maternal
Ab-mediated infant DHF/DSS in the context of pre-existing
anti-flavivirus immune sera other than anti-DENV immune
sera (Martinez Gomez et al., 2016; Ng et al., 2014). In compar-
ison, maternal DENV Abs exerted mainly neutral effects against
ZIKV in our mouse model, in agreement with the observation
that prior DENV immunity (1–3 years long) did not influence
subsequent ZIKV infection in macaques (McCracken et al.,
2017; Pantoja et al., 2017) and consistent with reports that
the anti-DENV Ab response in humans becomes less cross-
neutralizing against ZIKV over time (Collins et al., 2017;
Montoya et al., 2018). However, our result contrasts with a
published study demonstrating increased ZIKV infection and
pathogenesis in Stat2/mice that were passively transferred
with DENV-immune human plasma (Bardina et al., 2017). The
disparity in results may be related to the magnitude and quality
of Ab responses (e.g., binding, neutralization, isotype, speci-
ficity, and avidity) and perhaps the use of LysMCre+Ifnar1fl/fl
versus Stat2/mice.
By modeling a potential epidemiologic scenario in which
infants born to ZIKV-experienced women are infected with
DENV, our study has revealed a pathogenic potential of
ZIKV maternal Abs during DENV infection. Mouse versus
human differences related to the quantity and potentially
quality of maternal IgG transferred into infants may affect
the timing or duration of enhanced DENV pathogenesis in
human infants versus mice. In our mouse model, 4- to 5-
week-old pups born to flavivirus-naive mothers with either
short-term (2 months) or long-term (>6 months) exposure
to ZIKV exhibited increased dengue disease severity. In
humans, the magnitude and quality of the Ab response to
ZIKV may vary depending on the length of exposure (acute
versus early convalescence versus late convalescence) and
Figure 4. Administration of Anti-TNF Ab or
EDE1 C8 and C10 Abs, which Recognize
EDE1 Epitopes, Prevents Lethal Dengue Dis-
ease in Mice Born to ZIKV-Immune Mothers
Four- to 5-week-old LysMCre+Ifnar1fl/fl mice born to
mothers infected with ZIKV strain SD001 (106 FFU via
retro-orbital route) for 7–9 months (n = 3) were
treated via an intraperitoneal injection with 100 mg of
isotype control Ab (clone HPRN) or anti-TNF Ab
(clone XT3.11) on days 1, 2, and 3 following inocu-
lation with 106 FFU of DENV2 strain S221 via tail vein
injection.
(A–D) Clinical scores of isotype control Ab-treated
mice (n = 7) (A), clinical scores of anti-TNF Ab-treated
mice (n = 8) (B), and weight loss (C) and survival rates
(D) of isotype control Ab-treated mice (black circles)
and anti-TNF Ab-treated mice (open circles).
Administration of EDE1 C8 or EDE1 C10 Abs was
performed in 4- to 5-week-old LysMCre+Ifnar1fl/fl
mice born to mothers infected with ZIKV strain
SD001 (106 FFU via retro-orbital route) for
12–13 months (n = 4). These pups were injected via
an intraperitoneal route with PBS, EDE1 C8 Ab
(100 mg), or EDE1 C10 Ab (100 mg) on days 1, 2, and 3
following challenge with DENV2 strain S221 (106 FFU
via tail vein).
(E–H) Clinical scores of PBS control mice (n = 9) (E),
clinical scores of EDE1 C8 Ab-administered mice
(n = 10) (F), clinical scores of EDE1 C10 Ab-admin-
istered mice (n = 8) (G), and weight loss (H) and
survival rates (I) of PBS-treated (black circles), EDE1
C8-treated (open circles), and EDE1C10-treated (red
circles) mice.
Data are pooled from two independent experiments
and are expressed as mean ± SEM. Unpaired Stu-
dent’s t test of groups for each day was used in (C)
and (H). Log-rank test (*p < 0.05, **p < 0.01, ***p <
0.001, ****p < 0.0001) was used in (D) and (I).flavivirus-naive versus immune status of mothers (Collins 
et al., 2017; Montoya et al., 2018; Yu et al., 2017), thereby 
affecting the window of both potentially protective and path-
ogenic periods in infants.
In summary, our findings have implications for understanding 
DENV infections in countries with co-circulation of ZIKV and 
DENV or women with prior ZIKV immunity through natural 
infection or, possibly, vaccination. Mounting evidence supports 
a key role for ADE in pathogenesis of DENV infection in children 
and adults with secondary heterotypic DENV infection andinfants born to DENV-immune women
(Balsitis et al., 2010; Halstead, 2007; Katzel-
nick et al., 2017; Ng et al., 2014; Zellweger
et al., 2010). Our results suggest that if
women are infected with ZIKV or potentially
immunized with a ZIKV vaccine that elicits a
cross-reactive Ab response, their infants
might have an increased risk of developing
DHF/DSS. A ZIKV vaccine with fusion loop
mutations in the E protein has been re-
ported to reduce cross-reactive Ab re-
sponses and minimize enhancement of
DENV infection and pathogenesis in mice(Richner et al., 2017), suggesting one potential avenue for
designing ZIKV vaccines that avoid ZIKV maternal Ab-mediated
severe DENV disease in infants. Thus, the emergence of ZIKV
immunity in DENV-endemic regions may create an added risk
for ADE-mediated severe dengue disease. Our mouse model
may be useful for testing the effects of ZIKV and DENV (including
different serotypes) on infant DENV and ZIKV infections and for
evaluating the effects of ZIKV and DENV vaccine candidates
that are designed for deployment in DENV-endemic regions.
As T, B, and most dendritic cell responses are normal in
LysMCre+Ifnar1fl/flmice, this mousemodel may also be useful for
investigating mechanisms of DENV pathogenesis and immunity.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Viruses
SD001 is a ZIKV clinical isolate obtained from an adult female traveler infected in Caracas, Venezuela in 2016 (A.F.C. et al., 
unpublished data). Infectious virus was isolated from a filtered urine sample from patient SD001 and propagated in C6/36 Aedes 
albopictus cells (ATCC, cat. # ATCC: CRL 1660). Mouse-adapted DENV2 strain S221 was propagated in C6/36 cells. ZIKV-
SD001 and DENV2-S221 were titrated by focus-forming assay using baby hamster kidney (BHK-21) (ATCC, cat. #ATCC: CCL 10) 
cells as described in the virus quantification section.
Cell Lines
C6/36 mosquito cells were propagated in Leibovitz’s L-15 (Thermo Fisher Scientific, cat. #11415064) supplemented with 10%
fetal bovine serum (FBS) (Thermo Fisher Scientific, cat. #16000044), 1% penicillin/streptomycin (Thermo Fisher Scientific cat. 
#15140-122), and 1% HEPES (Thermo Fisher Scientific, cat. #15630080) at 28C. BHK-21 cells were grown in MEM a (Fisher, 
cat. #12-561-072) supplemented with 10% FBS, 1% penicillin/streptomycin, and 1% HEPES at 37C in a 5% CO2 atmosphere. 
U937-DC-SIGN cells were propagated in RPMI 1640 (Thermo Fisher Scientific, cat. #11875093) supplemented with 10% FBS, 
1% penicillin/streptomycin, and 1% HEPES at 37C in a 5% CO2 atmosphere.
Mice
LysMCre+Ifnar1fl/fl C57BL/6 mice lack type I interferon (IFN) receptors in a subset of myeloid cells (Clausen et al., 1999; Diamond 
et al., 2011) and were characterized previously as a model for DENV (Pinto et al., 2015; Zust et al., 2014) and ZIKV (Elong Ngono 
et al., 2017; Tang et al., 2016) infection. Female mice were inoculated via retro-orbital route with 106 focus-forming units (FFU) of 
ZIKV-SD001 diluted in 10% FBS/PBS (100 mL total volume) or with 5 x 105 FFU of DENV2-S221 via tail vein injection. At four weeks 
post-ZIKV or DENV infection, females were bred with naive 6- to 8-week old male LysMCre+Ifnar1fl/fl mice. Male and female pups 
born to ZIKV- or DENV-infected LysMCre+Ifnar1fl/fl females were challenged at 4- to 5-weeks of age. Analyses were not performed 
on whether or not the sex of the mouse influenced the overall outcome as the outcome did not differ based on the sex of the mouse. 
Four- to 5-week-old age-matched pups (both males and females) born to naive LysMCre+Ifnar1fl/fl mothers were used as controls. 
The mothers’ ZIKV or DENV infection lengths are stated in each figure legend. All experiments were performed following the La Jolla 
Institute Animal Care and Use Committee-approved animal protocol #AP 00001029. Mice were housed at a maximum of 5 per cage 
with the same sex of mouse. Water, food, and housing with bedding and enrichment were autoclaved prior to being utilized. Cages 
were changed every 2 weeks under a laminar flow hood. Proper personal protective equipment was worn when in the vivarium and 
handling the mice. All mice were bred and maintained under specific pathogen free (SPF) conditions, and infected mice were housed 
in a BSL2 SPF room.
METHOD DETAILS
Disease Scoring
Pups born to ZIKV-immune or naive mothers at 4- to 5-weeks of age were inoculated with 1 x 106 FFU of DENV2 S221 diluted in 10%
FBS/PBS (200 mL total volume) per mouse via tail vein injection. Miceweremonitored daily for weight and clinical scores from day 0 to
day 20 p.i. Clinical scores ranged from 1 - 7: 1, heathy mice with a smooth coat and bright, alert eyes; 2, mice are slightly ruffled
around the head and neck, but active and alert; 3, mice have a ruffled coat throughout the body, but still active and alert; 4, mice
have a very ruffled coat and slightly closed eyes, they walk slowly, and they have mild lethargy; 5, mice have a very ruffled coat
and closed inset eyes, slow to no movement but will return to the upright position if put on the side; 6, mice have a very ruffled
coat and closed inset eyes, are moribund, they have no movement or uncontrollable spastic movements, will not return to upright
position if put on its side, and completely unaware or in noticeable distress and require humane euthanasia; 7, mice are deceased.
Mice were humanely euthanized if weight loss was greater than or equal to 20% of their body mass or if their clinical score was a 6.
Flow Cytometric Analysis of Immune Cell Populations
Spleens were harvested from pups born to ZIKV-immune or naive mothers at 4-5 weeks of age after being humanely euthanized with
CO2. Splenocytes were plated into 96-well round-bottom plates at 1 x 10
6 cells/well in RPMI 1640 medium supplemented with 10%
FBS, 1% penicillin/streptomycin, and 1% HEPES. Splenocytes were washed with PBS and stained with anti-CD3 PerCP-Cy5.5
(Tonbo Biosciences, cat. #65-0031-U100), anti-CD4 APC eflour780 (Thermo Fisher Scientific, cat. #47-0041-82), and anti-CD8
BV510 (BioLegend, cat. #100751) or with anti-CD19 PE (Thermo Fisher Scientific, cat. #12-0193-83), anti-CD138 PerCP-Cy5.5
(BioLegend, cat. #142510), and anti-mouse IgD FITC (BD Biosciences, cat. #553439). Cells were incubated with these Abs (each
at 1:200 dilution) for 30 min, followed by washing for 3 times with FACs buffer. The cells were then fixed and permeabilized with
Cytofix/Cytoperm (BD Biosciences, cat. #554714), washed and resuspended in FACs buffer.
Infectious Virus Quantification
Four- to 5-week old LysMCre+Ifnar1fl/fl mice born to ZIKV-immune or naive mothers were inoculated with 2 x 105 FFU DENV2 S221
diluted in 10% FBS/PBS via tail vein injection (200 mL total volume) or with 1 x 105 FFU ZIKV in 10% FBS/PBS retro-orbitally (100 mL
total volume). Mice were humanely euthanized with CO2 3 days p.i. Blood was obtained via cardiac puncture, centrifuged (16,363 x g
for 15 min at 4C), and serum was stored at -80C. Mice were perfused with PBS. Spleen and livers were harvested and put in pre-
weighed tubes containing complete MEM a containing a metal bead and stored at -80C. Viral titers were measured using a BHK-21
cell-based focus forming assay (FFA). BHK-21 cells were plated at 2 x 105 cells per well in a 24-well plate and incubated overnight in
complete MEM a medium supplemented with 10% FBS, 1% penicillin/streptomycin, and 1% HEPES at 37C in a 5% CO2 atmo-
sphere. Cells were infected with serial dilutions of virus for 1.5 hr with gentle shaking every 15 min. The medium was then aspirated
and replaced with fresh MEM a supplemented with 1% carboxymethyl cellulose (Sigma, cat. #419273), 10% FBS, 1% penicillin/
streptomycin, and 1%HEPES. Cells were then cultured for 3 days. At 3 days p.i., cells were fixed with 4% formalin (Fisher Scientific,
cat. #SF98-4) for 30 min, washed 3 times with PBS, permeabilized with 1% Triton X-100 (Sigma, cat. #X100-100ML) for 30 min,
washed 3 times with PBS, and blocked by 10% FBS in PBS for 30 min. ZIKV or DENV was detected by incubation of cells with
4G2, a pan-flavivirus E protein-specific monoclonal Ab (ATCC, cat. # D1-4G2-4-15 (ATCC HB-112)) (1 mg/mL in 1% FBS/PBS) for
1.5 h at room temperature or overnight at 4C. Cells were washed 3 times with PBS and incubated for 1.5 h with horseradish perox-
idase (HRP)-conjugated goat anti-mouse IgG (Jackson ImmunoResearch, cat. #115-035-072) (diluted 1:1000 in 1% bovine serum
albumin (BSA)/PBS), followed by washing 3 times with PBS. Finally, foci were detected by incubation with KPL True Blue substrate
(SeraCare, cat. #5510-0030) for 20 min and rinsed in diH2O.
Viral RNA Quantification
Four- to 5-week-old LysMCre+Ifnar1fl/fl mice born to ZIKV-immune or naive mothers were inoculated with 2 x 105 FFU DENV2 S221
diluted in 10% FBS/PBS (200 mL total volume) via tail vein injection. Mice were humanely euthanized 3 days p.i. Blood was obtained
via cardiac puncture, centrifuged (16,363 x g for 15 min at 4C), and serum was stored at -20C. Mice were perfused with PBS, and
their spleens and livers were harvested and stored in RNAlater (Thermo Fisher Scientific, cat. #AM7021) at 4C. Tissues were homog-
enized prior to RNA extraction. RNA was isolated via Qiagen QIAmp viral mini kit (Qiagen, cat. #52904) and qRT-PCRwas performed
as previously described (Prestwood et al., 2008) using the QuantaBio qScript one-step qRT-PCR kit (VWR, cat. #101414-172) and
probes and primers described in the Key Resources Table. PCRmixtures were pre-incubated at 50C for 2 min, then 95C for 10 min
followed by 40 cycles of two-step incubations at 95C for 15 s and 60C for 1 min for DENV2. DENV2 samples were compared to a
standard curve of 103 – 107 copies of DENV2 RNA. 18S samples were diluted and compared to a standard of 18S rRNA that was
derived from a mouse spleen and diluted to 102 – 104 18S RNA. 18S RNA was ran for 10 min at 48C, 5 min at 98C, and 39 cycles
of 15 seconds at 95C and 1 min at 60C.
ZIKV and DENV ELISA
Serum samples frommice born to ZIKV- or DENV-immunemothers were tested for ZIKV- andDENV-binding antibodies using a direct
ELISA. To detect DENV antibodies, sucrose purified DENV2 S221 virions were used at a concentration of 1 x 106 FFU/well as the
coating antigen and UV-inactivated. DENV2 was diluted in 50 mL coating buffer (0.1M NaHCO3 in PBS) per well and incubated at
4C overnight. Wells were washed 3 times with ELISA washing buffer (0.05% Tween20 in PBS) and then blocked with 5% casein in 
PBS for an hour at room temperature. Serum was first diluted 1:10 in 10% FBS/PBS and then 1:3 for subsequent dilutions and was 
incubated in wells for 1.5 hr at room temperature. Wells were washed 3 times with ELISA washing buffer. Wells were then incubated 
with peroxidase conjugated Affini-Pure Goat anti-mouse IgG Fcg (Jackson ImmunoResearch, cat. #115-035-008) diluted 1:5000 in 
1% BSA/PBS at room temperature. Wells were washed 3 times with ELISA washing buffer. 100 mL of TMB substrate solution was 
added until blue color change, and reaction was stopped with 50 mL of 2N sulfuric acid (Sigma, cat. #339741). To detect ZIKV 
Abs, ZIKV E protein (Suriname strain, Native Antigen Company, #ZIKVSU-ENV) was adsorbed to 96-well plates at a concentration 
of 1 mg/mL in coating buffer (0.1M NaHCO3 in PBS) overnight at 4C and the remaining steps were the same as the DENV ELISA.
Neutralization Assays
Serum samples from naive pups born to ZIKV- or DENV-immune mothers were used in a standard flow cytometry-based neutrali-
zation assay using U937-DC-SIGN cells (Wen et al., 2017). Mouse serum was inactivated at 56C for 30 min . Sera were diluted 
at 1:10 and then at 1:3 for subsequent dilutions up to 1:7290 and then incubated with 105 FFU of DENV2 S221 or with 6 x 104 
FFU ZIKV-SD001 in RPMI 1640 supplemented with 1% penicillin/streptomycin and 1% HEPES in a 96-well round bottom plate. Virus 
and sera were incubated together at 37C with 5% CO2 for 1 hr . U937-DC-SIGN cells were then seeded into each well (105 cells per 
well in a 96-well round bottom plate), followed by addition of the virus/serum mixture to cells. Plates were incubated at 37C with 5%
CO2 for 2 hr , rocking every 15 min . Plates were then centrifuged at 300 x g for 5 min and media was replaced with RPMI 1640 
(supplemented with 10% FBS, 1% penicillin/streptomycin, and 1% HEPES). Sixteen hours later, cells were stained with PE-labeled 
anti-human CD209 diluted 1:100 (BD Pharmingen, cat. #551265), fixed and permeabilized with Cytofix/Cytoperm (BD Biosciences, 
cat. #554714), and then stained with FITC-labeled anti-flavivirus E protein antibody (clone 4G2) diluted 1:100. 4G2 was conjugated to 
Pierce FITC using an antibody labelling kit (Thermo Fisher Scientific, cat. #53027).
TNF Blockade
At days 1, 2, and 3 post challenge with DENV, pups born to ZIKV-immune mothers (n = 3 mothers infected for 7-9 months) were 
treated via intraperitoneal injection with 100 mg of anti-TNF (BioXcell, clone XT3.11, Rat IgG1, cat. #BE0058) or an isotype control 
(BioXcell, clone HRPN, Rat IgG1, cat. #BE0088) Ab that was diluted in PBS (200 mL total volume per mouse). Mice were clinically 
scored, weighed, and monitored for survival, on a daily basis, until day 20 p.i.
Passive Transfer of IgG
Serum IgG was purified from 4- to 5-week-old mice that were born to naive or ZIKV-immune mothers. For the first IgG preparation, 
serum was isolated from 23 4- to 5-week old mice from 3 different ZIKV-immune mothers and 20 naive mice from 2 different mothers. 
For the second IgG preparation, serum was isolated from 13 4- to 5-week-old mice from 2 different ZIKV-immune mothers and 9 
naive mice from 2 different mothers. IgG was isolated from the pooled serum using the NAb protein G spin columns, 1 mL (Thermo 
Fisher Scientific, cat. #89957). Buffer was exchanged with PBS by the Slide-a-lyzer dialysis cassettes, 2K molecular weight cut-off, 
12 mL (Thermo Fisher Scientific, cat. #66212) per manufacturer’s directions. The isolated IgGs were injected via intraperitoneal route 
into 4- to 5-week old naive LysMCre+Ifnar1fl/fl mice 30 min prior to inoculation with 2 x 105 FFU of DENV2 S221 via the tail vein. Three 
days p.i., mice were humanely euthanized. Blood was drawn, serum was isolated, and spleens and livers were harvested.
TNF ELISA
Serum samples from mice that received IgG was assessed for TNF levels using a R&D Systems quantikine ELISA kit (R&D Systems, 
cat. #MTA00B). 52 mL of the serum from each recipient mouse that received 145 mg of IgG was assessed to determine levels of TNF 
using the kit protocol.
Monoclonal Ab Treatment
At days 1, 2, and 3 post challenge with DENV2, pups born to ZIKV-immune mothers (n=4 mothers infected for 12-13 months) were 
treated via intraperitoneal injection with 100 mg of monoclonal Ab (C8 or C10) recognizing the DENV E-dimer epitope (EDE) (Dejnir-
attisai et al., 2015) diluted in PBS to a total of 200 mL total volume per mouse. Both EDE1-C8 and EDE1-C10 Abs were produced 
recombinantly (Swanstrom et al., 2016). Mice were clinically scored, weighed, and monitored for survival on a daily basis for 
20 days p.i.
QUANTIFICATION AND STATISTICAL ANALYSIS
Flow Cytometric Analysis of Immune Cell Populations
Following Ab staining, splenocytes were resuspended in FACs buffer and analyzed on the LSRII flow cytometer. Data were analyzed 
using FlowJo software X 10.0.7 (Tree Star).
Infectious Virus Quantification
Infectious viral foci were detected by True Blue peroxidase substrate reaction and counted manually. Viral titers were expressed as 
log FFU/g tissue or log FFU/mL serum.
Viral RNA Quantification
DENV2 RNA was quantified using the CFX96 Touch real-time PCR detection system (Bio-Rad CFX Manager 3.1) and normalized to
volume for serum and to 18S RNA levels for spleens and livers.
ZIKV and DENV ELISA
ZIKV and DENV specific IgG were detected by TMB reaction. Signals were quantified using a Spectramax M2E at 450 nm.
Neutralization Assays
After Ab staining, infected U937-DC-SIGN cells were resuspended in FACS buffer and analyzed on the LSRII flow cytometer. Data
were analyzed using FlowJo software X 10.0.7 (Tree Star). Percent inhibition was calculated by taking the value of % infection of the
control with no serum - % infection of sample and dividing all by the value of % infection of the control with no serum.
Statistical Analysis
n demonstrates the number of mice used per experiment. For Figures 1A–1D: 11 male and female pups were used from 2
naive mothers and 15 male and female pups were used from 3 ZIKV-immune mothers that were infected for 8-12 months; Figures
1E–1H: 8 male and female mice were used from 2 naive mothers and 8 male and female mice from 2 ZIKV-immune mothers infected
for 2 months; Figure 1I: 11 male and female pups from 2 naive mothers and 13 male and female pups from 4 ZIKV-immune mothers
infected for 6-13 months; Figure 1J: 7 female and male pups from 2 naive mothers and 7 male and female pups from 2 ZIKV-immune
mothers infected for 2months. For Figures 2A–2D: serumwas obtained from 10male and female pups born to 2 naivemothers and 13
male and female pups born to 4 ZIKV-immune mothers infected for 6-13 months; Figures 2E and 2F: serum from 10male and female
mice from 2 ZIKV-immune mothers infected for 2 months compared to serum obtained in Figures 2A–2D. For Figure 3: IgG was iso-
lated from 32 male and female pups born to 7 naive mothers and 36 male and female pups born to 8 ZIKV-immune mothers infected
for 6-12 months and 13 male and female mice from 3 naive mothers were used as recipient mice. For Figures 4A–4D: 15 male and
female mice from 3 ZIKV-immune mothers infected for 7-9 months; Figures 4E–4I 27 male and female mice from 4 ZIKV-immune
mothers infected for 12-13 months. n values can also be found in figure legends.
Data were analyzed using Graphpad Prism, version 7 (Graphpad Software). p values were obtained by using Mann Whitney test,
unpaired Student’s t test, one-way ANOVA or by using the log-rank test for survival curves. Goodness of fit tests were performed for
data analyzed by unpaired Student’s t tests to determine normal distribution of data as expected. Statistical details are described in
corresponding figure legends along with p values.
